ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that Dr Carl Firth, CEO, will present a company update at the H.C. Wainwright Global Investment Conference. The conference will be held virtually and in-person from May 23 to 26, 2022.

For more information, please refer to the press release.